Michael PT Lunn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8700653/publications.pdf

Version: 2024-02-01

96 papers 4,359 citations

30 h-index 62 g-index

100 all docs

100 docs citations

100 times ranked

6039 citing authors

#	Article	IF	CITATIONS
1	COVID-19 vaccination and Guillain-Barr $ ilde{A}$ © syndrome: analyses using the National Immunoglobulin Database. Brain, 2023, 146, 739-748.	7.6	57
2	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. Journal of Neurology, 2022, 269, 1470-1475.	3.6	5
3	CSF biomarkers for dementia. Practical Neurology, 2022, 22, 285-294.	1.1	3
4	Unusual upper limb features in <i>SORD</i> neuropathy. Journal of the Peripheral Nervous System, 2022, 27, 175-177.	3.1	4
5	IVIg-exposure and thromboembolic event risk: findings from the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 876-885.	1.9	10
6	Pragmatic guide to peripheral nerve disease and the role of clinical biomarkers. Practical Neurology, 2022, 22, 461-471.	1.1	2
7	Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain, 2021, 144, 682-693.	7.6	221
8	COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. Brain, 2021, 144, 357-360.	7.6	77
9	Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 172-176.	1.9	21
10	Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study. Brain Communications, 2021, 3, fcab168.	3.3	33
11	Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy. Journal of Neurology, 2021, 268, 1485-1490.	3.6	3
12	Preventing expensive harms in Guillain-Barré syndrome. Lancet Neurology, The, 2021, 20, 249-251.	10.2	0
13	Reply: Guillain-BarrA© syndrome, SARS-CoV-2 and molecular mimicry <1>and 1 Ongoing challenges in unravelling the association between COVID-19 and Guillain-BarrA© syndrome <i>association between COVID-19 and Guillain-BarrA© syndrome <i>and </i> Currently available data regarding the potential association between COVID-19 and Guillain-BarrA© syndrome. Brain, 2021, 144,</i>	7.6	4
14	Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain, 2021, 144, 1183-1196.	7.6	46
15	Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis. BMJ Neurology Open, 2021, 3, e000096.	1.6	4
16	<i>RFC1</i> expansions are a common cause of idiopathic sensory neuropathy. Brain, 2021, 144, 1542-1550.	7.6	63
17	Intravenous immunoglobulin treatment for mild Guillain-Barr $\tilde{A} \otimes$ syndrome: an international observational study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1080-1088.	1.9	6
18	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Forceâ€"Second revision. Journal of the Peripheral Nervous System, 2021, 26, 242-268.	3.1	176

#	Article	IF	CITATIONS
19	Paraproteinaemic neuropathy: MGUS and beyond. Practical Neurology, 2021, 21, 492-503.	1.1	11
20	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Forceâ€"Second revision. European Journal of Neurology, 2021, 28, 3556-3583.	3.3	153
21	Sex differences in immunological responses to COVID-19: a cross-sectional analysis of a single-centre cohort. British Journal of Anaesthesia, 2021, 127, e75-e78.	3.4	4
22	Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. EClinicalMedicine, 2021, 39, 101070.	7.1	21
23	Influence of IL-6 levels on patient survival in COVID-19. Journal of Critical Care, 2021, 66, 123-125.	2.2	7
24	Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. Brain Communications, 2021, 3, fcab099.	3.3	43
25	Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials. Neurotherapeutics, 2021, 18, 2351-2367.	4.4	12
26	An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy. Journal of the Peripheral Nervous System, 2021, 26, 461-468.	3.1	3
27	Predicting longâ€ŧerm trends in inflammatory neuropathy outcome measures using latent class modelling. Journal of the Peripheral Nervous System, 2021, , .	3.1	3
28	Developments in clinical testing of cerebrospinal fluid biomarkers of Alzheimer's disease in the UK. Alzheimer's and Dementia, 2021, 17, .	0.8	0
29	Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 113-121.	1.9	34
30	IgM paraproteinâ€associated peripheral neuropathy: small CD20â€positive Bâ€cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness. British Journal of Haematology, 2020, 188, 511-515.	2.5	5
31	A case of limbic encephalitis associated with asymptomatic COVID-19 infection. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1229-1230.	1.9	52
32	MRI quantifies lumbosacral nerve root and sciatic nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Radiology, 2020, 130, 109164.	2.6	6
33	Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes. Muscle and Nerve, 2020, 62, 617-625.	2.2	19
34	High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry. Blood Advances, 2020, 4, 2139-2142.	5.2	13
35	Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome. Journal of Neuroinflammation, 2020, 17, 86.	7.2	44
36	Clinical characteristics, risk factors, and outcomes of POEMS syndrome. Neurology, 2020, 95, e268-e279.	1.1	28

3

#	Article	IF	CITATIONS
37	The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain, 2020, 143, 3104-3120.	7.6	880
38	Thromboembolic risk with IVIg. Neurology, 2020, 94, e635-e638.	1.1	25
39	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2020, 74, 1189-1201.	2.6	38
40	Neurology in the time of COVID-19. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 568-570.	1.9	53
41	High-Dose Methotrexate Based Therapy for the Treatment of Bing Neel Syndrome. Blood, 2020, 136, 12-13.	1.4	1
42	OUP accepted manuscript. Brain, 2020, 143, e101.	7.6	12
43	Plasma Exchange for COVID-19 Thrombo-Inflammatory Disease. Blood, 2020, 136, 27-27.	1.4	1
44	Neuropathy with IgM Gammopathy: Incidence, Characteristics and Management, a Rory Morrison W.M.U.K Registry Analysis. Blood, 2020, 136, 1-2.	1.4	2
45	Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. Journal of the Peripheral Nervous System, 2019, 24, 314-319.	3.1	46
46	The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy – A prospective, pilot observational study. PLoS ONE, 2019, 14, e0211184.	2.5	64
47	Highâ€dose therapy and autologous transplantation for POEMS Syndrome: effective, but how to optimise?. British Journal of Haematology, 2019, 186, e178-e181.	2.5	9
48	Prevalence and Course of Endocrinopathy in POEMS Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2140-2146.	3.6	20
49	Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome. Journal of Neurology, 2019, 266, 1067-1072.	3.6	15
50	086â€Clinical, investigational and treatment factors do not determine prognosis of patients with inflammatory neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A27.3-A28.	1.9	0
51	Neuropathies and paraproteins. Current Opinion in Neurology, 2019, 32, 658-665.	3.6	13
52	FM1-4â€Intraneural perineuriomas: radiologically classic, clinically varied. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, e21.3-e20.	1.9	0
53	Diagnosis of amyloid neuropathy. Practical Neurology, 2019, 19, 250-258.	1.1	17
54	Advances in <scp>POEMS</scp> treatment and the need to define standardised outcome measures. British Journal of Haematology, 2019, 185, 386-388.	2.5	0

#	Article	IF	CITATIONS
55	CSF Beta-amyloid $1\hat{a}\in$ "42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study. Annals of Surgery, 2019, 269, 1200-1205.	4.2	56
56	High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines. Blood, 2019, 134, 714-714.	1.4	0
57	POEMS neuropathy: optimising diagnosis and management. Practical Neurology, 2018, 18, 278-290.	1.1	17
58	A diagnostic conundrum. Practical Neurology, 2018, 18, 137-142.	1.1	1
59	Amyloid \hat{l}^2 peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 311-321.	2.4	21
60	Complexity of the Genetics and Clinical Presentation of Spinocerebellar Ataxia 17. Frontiers in Cellular Neuroscience, 2018, 12, 429.	3.7	21
61	POEMS syndrome. Current Opinion in Neurology, 2018, 31, 551-558.	3.6	24
62	Raised VEGF. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e486.	6.0	24
63	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurology, The, 2018, 17, 689-698.	10.2	48
64	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer's Research and Therapy, 2018, 10, 32.	6.2	79
65	Investigation and management of IgM and Waldenströmâ€associated peripheral neuropathies: recommendations from the <scp>IWWM</scp> â€8 consensus panel. British Journal of Haematology, 2017, 176, 728-742.	2.5	58
66	The predictive value of T-tau and AB1-42 levels in idiopathic normal pressure hydrocephalus. Acta Neurochirurgica, 2017, 159, 2293-2300.	1.7	19
67	Inhibition of complement in Guillainâ€Barré syndrome: the <scp>ICAâ€GBS</scp> study. Journal of the Peripheral Nervous System, 2017, 22, 4-12.	3.1	70
68	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- \hat{l}^2 Concentration. Journal of Alzheimer's Disease, 2017, 56, 885-891.	2.6	6
69	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. Journal of Alzheimer's Disease, 2016, 54, 1297-1302.	2.6	21
70	A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. Journal of the Peripheral Nervous System, 2016, 21, 33-37.	3.1	59
71	Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. The Cochrane Library, 2015, 2015, CD007115.	2.8	294
72	Do cerebrospinal fluid transfer methods affect measured amyloid \hat{l}^242 , total tau, and phosphorylated tau in clinical practice?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 380-384.	2.4	5

#	Article	IF	CITATIONS
73	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 440-446.	2.4	16
74	Comparing the <scp>NIS</scp> vs. <scp>MRC</scp> and <scp>INCAT</scp> sensory scale through Rasch analyses. Journal of the Peripheral Nervous System, 2015, 20, 277-288.	3.1	27
75	Future needs in peripheral neuropathy outcome measures. Journal of the Peripheral Nervous System, 2015, 20, 341-346.	3.1	0
76	Grip strength comparison in immuneâ€mediated neuropathies: Vigorimeter vs. Jamar. Journal of the Peripheral Nervous System, 2015, 20, 269-276.	3.1	28
77	Impairment measures versus inflammatory <scp>RODS</scp> in <scp>GBS</scp> and <scp>CIDP</scp> : a responsiveness comparison. Journal of the Peripheral Nervous System, 2015, 20, 289-295.	3.1	30
78	Outcome measures in neuromuscular disease: isÂtheÂworld still flat?. Journal of the Peripheral Nervous System, 2015, 20, 255-259.	3.1	7
79	Endoscopic and Open Release Similarly Safe for the Treatment of Carpal Tunnel Syndrome. A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0143683.	2.5	69
80	Whippits, nitrous oxide and the dangers of legal highs. Practical Neurology, 2015, 15, 207-209.	1.1	109
81	Tremor in Charcot-Marie-Tooth disease: No evidence of cerebellar dysfunction. Clinical Neurophysiology, 2015, 126, 1817-1824.	1.5	22
82	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. Journal of Neurology, 2015, 262, 2722-2730.	3.6	39
83	PERIPHERAL NERVE BING-NEEL SYNDROME. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.59-e4.	1.9	3
84	THE NEUROPATHY SPECTRUM IN WALDENSTRöM'S MACROGLOBULINAEMIA. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.60-e4.	1.9	0
85	Neuropsychiatric systemic lupus erythematosus: a diagnostic challenge. BMJ Case Reports, 2015, 2015, bcr2014208215-bcr2014208215.	0.5	7
86	Truncating and Missense Mutations in IGHMBP2 Cause Charcot-Marie Tooth Disease Type 2. American Journal of Human Genetics, 2014, 95, 590-601.	6.2	75
87	SEE NO EVIL, HEAR NO EVIL, SPEAK NO EVIL… KEEP IT A SICRET. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.142-e4.	1.9	0
88	Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain, 2014, 137, 2178-2192.	7.6	430
89	SENSORY NEURONOPATHY; A CASE REPORT AND A REVIEW OF THE ROLE OF GANGLION NERVE BIOPSY IN DIAGNOSIS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.127-e2.	1.9	1
90	Tremor in inflammatory neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1282-1287.	1.9	129

#	Article	lF	CITATIONS
91	Cerebellar learning distinguishes inflammatory neuropathy with and without tremor. Neurology, 2013, 80, 1867-1873.	1.1	30
92	Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies., 2012,, CD002827.		33
93	The International Inflammatory Neuropathy Consortium. Journal of the Peripheral Nervous System, 2007, 12, 235-236.	3.1	O
94	Pinpointing peripheral neuropathies. Practitioner, 2007, 251, 67-8, 71-4, 76-7 passim.	0.3	1
95	Antiâ€myelinâ€associated glycoprotein antibodies alter neurofilament spacing. Brain, 2002, 125, 904-911.	7.6	86
96	Inflammatory and immunological diseases of the nervous system. , 0, , 585-592.		0